| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/28/2004 | US20040214834 Pyrazolo-pyridines for the treatment of herpes infections |
| 10/28/2004 | US20040214831 cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction |
| 10/28/2004 | US20040214830 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors |
| 10/28/2004 | US20040214829 Compositions containing alpha-2-adrenergic agonist components |
| 10/28/2004 | US20040214826 Method of treating sexual disturbances |
| 10/28/2004 | US20040214825 Method of treating sexual disturbances |
| 10/28/2004 | US20040214824 treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione |
| 10/28/2004 | US20040214823 Administering a fused aminoquinoline derivative such as (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij) quinoline-2(1H)-thione |
| 10/28/2004 | US20040214822 Substituted 4-aminocyclohexanol compounds |
| 10/28/2004 | US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| 10/28/2004 | US20040214819 Modified amino acids, pharmaceuticals containing these compounds and method for their production |
| 10/28/2004 | US20040214818 Alzheimer's disease; Parkinson's disease; Huntington's disease; cognition activators; learning enhancement; central nervous system disorders |
| 10/28/2004 | US20040214817 Diaminotriazoles useful as inhibitors of protein kinases |
| 10/28/2004 | US20040214816 Substituted imidazoles useful in the treatment of inflammatory diseases |
| 10/28/2004 | US20040214815 Therapeutic compounds |
| 10/28/2004 | US20040214814 Pyrazole compounds useful as protein kinase inhibitors |
| 10/28/2004 | US20040214813 Alkylated iminodibenzyls as antioxidants |
| 10/28/2004 | US20040214812 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors |
| 10/28/2004 | US20040214811 Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| 10/28/2004 | US20040214809 consists of a sulfite (sodium or potassium sulfite, bisulfite, or metabisulfite), a sulfite preservative (glycerol, methanol, ethanol, propanol, butanol) and an agent methylamine, ethylamine, propylamine, butylamine, tri-hydroxymethylaminomethane; carrier-free silver thiosulfate ion complexes |
| 10/28/2004 | US20040214807 Estrogenic compounds as anti-mitotic agents |
| 10/28/2004 | US20040214806 administering estratriene-3-ol; 3,17 alpha -estradiol; estrone; estriol; prevent or ameliorate retinal and optic nerve damage associated with glaucoma |
| 10/28/2004 | US20040214805 Method and compositions for treating pulmonary diseases |
| 10/28/2004 | US20040214803 1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor vitamin D3; for preventing and/or treating allograft rejection |
| 10/28/2004 | US20040214802 Dipyridamole, acetylsalicylic acid, and angiotensin II antagonist pharmaceutical compositions |
| 10/28/2004 | US20040214801 9-Substituted minocycline compounds |
| 10/28/2004 | US20040214800 for Disorders Treatable by Modulation of RNA (DTMRs) including viral, neurodegenerative and others caused or related to RNA function, structure, amounts and/or activities |
| 10/28/2004 | US20040214799 for suppression of cancer cell invasion and cancer metastasis |
| 10/28/2004 | US20040214797 Preserved pharmaceutical compositions comprising cyclodextrins |
| 10/28/2004 | US20040214796 for reducing cerebral lesion sizein the treatment of cerebral ischemia |
| 10/28/2004 | US20040214795 Treatment and prophylaxis of sepsis and septic shock |
| 10/28/2004 | US20040214794 perorally or rectally administering an effective amount of a lipopolysaccharide isolated from Escherichia coli |
| 10/28/2004 | US20040214793 In aitu applying to bone joints |
| 10/28/2004 | US20040214792 Methods of treating inflammation |
| 10/28/2004 | US20040214790 Method of treatment for central nervous system injury |
| 10/28/2004 | US20040214789 Therapeutics |
| 10/28/2004 | US20040214784 covalent conjugates with mono-, di- , poly- or thiaalkanoic acids; ability to adjust the solubility of steroidal molecules, lipophilicity and bioavailability by altering the structure and length of the acid chain; avoids or reduces the local irritation caused by the parent drug |
| 10/28/2004 | US20040214782 caused by infection from Eimeria bovis, Eimeria zuernii or E. aubernensis; administering macrolide antibiotics, azalide class, such as tilmicosin |
| 10/28/2004 | US20040214776 (truncated GDNF) proteins that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells |
| 10/28/2004 | US20040214769 Estrogen receptors |
| 10/28/2004 | US20040214765 Methods and means for inhibition of CDK4 activity |
| 10/28/2004 | US20040214762 administering serine protease inhibitors and optionally in combination with substance P or peptide hormones, for prophylaxis of nervous system disorders, autoimmune disorders and tissue regeneration processes, such as wound healing |
| 10/28/2004 | US20040214759 Compositions and methods of use for a fibroblast growth factor |
| 10/28/2004 | US20040214752 Dispersible pharmaceutical compositions |
| 10/28/2004 | US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist |
| 10/28/2004 | US20040214332 Stable, multipotent transgenic nervous system progenitor tissue for treatment and prevention of neurodegenerative disorders |
| 10/28/2004 | US20040214275 Von willebrand factor (vmf)-cleaving enzyme |
| 10/28/2004 | US20040214261 culturing genetically modified microorganism containing polyglutamyl hydrolase (from rodents, mammals, or humans) activity to enhance generation of monoglutamyl folate; food processing; dairy products |
| 10/28/2004 | US20040214257 Method for the treatment of vitamin D related disease |
| 10/28/2004 | US20040214251 Immunogenic label for detection of low concentrations of viral therapeutics/antibodies in blood; diagnosing/detecion/monitoring viral drug resistance; immunoassay |
| 10/28/2004 | US20040214231 Methods of testing for allergic diseases,and therapeutic agents for treating same |
| 10/28/2004 | US20040214188 Diagnosis and treatment of diabetic , muscle, metabolic and eating disorders |
| 10/28/2004 | US20040214158 Treatment of human papillomavirus (hpv)-infected cells |
| 10/28/2004 | US20040214019 Covalently attaching to the surface a functionalized silicon compound include at least one activated silicon group and at least one derivatizable functional group |
| 10/28/2004 | US20040213860 compositions which are effective in preventing and/or treating peptic ulcer diseases, comprising an effective amount of American ginseng and/or its extract |
| 10/28/2004 | US20040213856 Compositions and methods for treatment of multiple myeloma |
| 10/28/2004 | US20040213855 Pharmaceutical composition for the treatment of acute disorders |
| 10/28/2004 | US20040213853 Stable nutritional powder containing ascorbyl palmitate |
| 10/28/2004 | US20040213850 Sustained release delivery of a thrombin inhibitor |
| 10/28/2004 | US20040213849 Modified release dosage forms |
| 10/28/2004 | US20040213848 Modified release dosage forms |
| 10/28/2004 | US20040213846 exfoliated clay; useful in the application of agricultural chemicals directly onto the surfaces of leaves; or the application of active ingredients such as perfumes or pharmaceutical compounds onto skin |
| 10/28/2004 | US20040213845 comprises a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent |
| 10/28/2004 | US20040213842 Particularly a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa) and/or activity-dependent sodium channel modulators to treat inflammatory bowel disorders, irritable bowel syndrome, slow-transit constipation, non-ulcer dyspepsia, an evacuation an evacuation disorder and functional dysphasia |
| 10/28/2004 | US20040213841 administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof |
| 10/28/2004 | US20040213839 by maintaining the agent, a flavorant, and a cellulosic material in relatively close physical contact with one another in an oral dosage form |
| 10/28/2004 | US20040213833 certain MMP inhibitory peptides improve the targeting of liposomes to cancer cells and enhance the uptake thereof by such cells |
| 10/28/2004 | US20040213832 non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at a rate and in an amount sufficient to induce and maintain analgesia over a period of at least three days, and up to 7 days to a patient in need thereof |
| 10/28/2004 | US20040213830 Stabilized silver-ion amine complex compositions and methods |
| 10/28/2004 | US20040213829 Cleansing the body of heavy metals with a primary chelator to move a heavy metal species from the central nervous system into the vascular system; and a secondary chelator to capsure and move the metal into an excretion pathway. |
| 10/28/2004 | US20040213826 medical device for use in inhibiting proliferation and/or migration of smooth muscle cells, wherein the medical device has a coating comprising an HDAC inhibitor |
| 10/28/2004 | US20040213819 Cosmetic composition |
| 10/28/2004 | US20040213816 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 10/28/2004 | US20040213808 immunogenic compositions containing as active ingredients recombinantly-produced forms of truncated flavivirus envelope and non-structural glycoproteins; may also include an adjuvant, such as saponin or a saponin-like material |
| 10/28/2004 | US20040213796 Immunotherapy for chronic myelocytic leukemia |
| 10/28/2004 | US20040213790 VEGF-related protein |
| 10/28/2004 | US20040213782 Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure |
| 10/28/2004 | US20040213776 Mycobacterium tuberculosis (MTB) targets for antibiotic therapy |
| 10/28/2004 | US20040213773 Composition and method for treating non-bacterial cystitis |
| 10/28/2004 | US20040213769 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 10/28/2004 | US20040213762 A viral vector containing a nucleic acid sequence encoding V3 polypeptide or a biologically active fragment of the V3 |
| 10/28/2004 | US20040213758 Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
| 10/28/2004 | US20040213757 adding a solvent to 11-desacetyl-11-(1-iodoacetyl)-wortmannin to obtain a solution; adding a tertiary amine to the solution;adding mPEG-sulfhydryl 5000 to the solution, stirring, adding ether, collecting the solid and washing with an ether to obtain pegylated wortmanin derivative |
| 10/28/2004 | US20040213756 Methods and compositions to treat myocardial conditions |
| 10/28/2004 | US20040213749 A dermal formulation for external use, contains sodium cromoglycate and a monoester of polyvalent alcohol and salicylic acid contained in a base; keeps skin healthy and demonstrates a sufficient effect in treating skin diseases |
| 10/28/2004 | US20040213744 can be sprayed onto skin to form a breathable film or patch, which remains stable and in place over a period of days;comprises at least one medicament, at least one film former and at least one vehicle |
| 10/28/2004 | US20040213442 Novel fatty acids analogous |
| 10/28/2004 | US20040211935 Multi-purpose acid compositions |
| 10/28/2004 | DE19911053B4 Kosmetische und/oder pharmazeutische Zubereitungen Cosmetic and / or pharmaceutical preparations |
| 10/28/2004 | DE10392164T5 Oral verabreichbare pharmazeutische Formulierung Orally administrable pharmaceutical formulation |
| 10/28/2004 | DE10315702A1 Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis Using Arzneitmittelkombinationen for the treatment of benign prostatic hyperplasia or for the treatment of abacterial prostatitis |
| 10/28/2004 | DE10297369T5 Anwendung von Oligosacchariden in kosmetischen oder dermatologischen Zusammensetzungen zum Stimulieren der Haftung von Keratinozyten an den Hauptproteinen der Lederhaut-Epidermis-Verbindung und zum Wiederherstellen der Epidermiskohäsion Application of oligosaccharides in cosmetic or dermatological compositions for stimulating the adhesion of keratinocytes to the main proteins of the dermis-epidermis compound and for restoring the Epidermiskohäsion |
| 10/28/2004 | CA2811272A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2803922A1 Once daily formulations of tetracyclines |
| 10/28/2004 | CA2559670A1 Stable amlodipine maleate formulations |
| 10/28/2004 | CA2527175A1 Remedies for diseases to be applied to eye |
| 10/28/2004 | CA2527170A1 Therapeutic compounds |
| 10/28/2004 | CA2526899A1 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 10/28/2004 | CA2522985A1 Means and methods for diagnosing and treating affective disorders |
| 10/28/2004 | CA2522802A1 Biologically active substance-immobilized device |